Pfizer’s Exubera Cost-Effectiveness Estimates Not Realistic, U.K.’s NICE Says
Executive Summary
Pfizer's cost-effectiveness estimates for Exubera submitted to the U.K.'s National Institute for Health & Clinical Excellence are not in line with clinical realities, a NICE committee said